Trametinib Alters Contractility of Paediatric Noonan Syndrome-Associated Hypertrophic Myocardial Tissue Slices
ESC Heart Failure · 01.06.2025 · 12 (3) · 2321-2334
DOI: 10.1002/ehf2.15173 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 21.11.2024. Verfasst von Jules Hamers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Surgical Research at the Walter Brendel Centre of Experimental Medicine, University Hospital of Munich, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Pyrimidinones, Myocardial Contraction, Pyridones, Noonan Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsches Zentrum für Herz-Kreislaufforschung, Deutsche Herzstiftung e.V..
Abstract (Originalsprache)
Aims
No curative treatment is available for RASopathy-associated childhood-onset hypertrophic cardiomyopathy (RAS-CM). Preclinical data and individual reports suggest a beneficial effect of small molecules targeting the RAS–mitogen-activated protein (MAP) kinase (MAPK) pathway in severely affected RAS-CM patients. The aim of this study was to evaluate the biophysical effects of trametinib, rapamycin and dasatinib on cultivated myocardial tissue slices of a paediatric RAS-CM patient using biomimetic cultivation chambers (BMCCs) and to correlate the findings with clinical data.
Methods
Contracting right ventricular (RV) tissue slices were prepared from resected myocardium, cultivated in BMCCs and treated with distinct molecules directly and indirectly targeting the RAS–MAPK pathway (trametinib, rapamycin and dasatinib) or dimethyl sulfoxide (DMSO). Tissue biophysical properties were assessed using electrical stimulation protocols. Contractile function, force–frequency relationship and post-pause potentiation were compared before and after treatment. These parameters correlated to L-type Ca2+ channel function and sarcoplasmic Ca2+ loading.
Results
In vivo, off-label treatment with MAPK kinase (MEK) inhibitor trametinib of a child with severe RAS-CM resulted in a modest reduction of RV outflow tract (RVOT) obstruction (RVOT 151 to 122 mmHg after 11 weeks) and improved diastolic function (E/A 0.68 to 1.09 after 11 weeks) and myocardial strain [RV global radial strain (RV-GRS) 25.94 to 42.76; RV global circumferential strain (RV-GCS) −15.26 to −18.61; and RV global longitudinal strain (RV-GLS) −10.31 to −16.78 at 11 weeks], as determined by echocardiography and cardiac magnetic resonance tomography. In cultivated RV myocardial tissue slices, contraction force decreased after addition of trametinib and rapamycin but not after addition of DMSO and dasatinib. Improvement of Ca2+ handling, as depicted by a more positive force–frequency relationship and enhanced post-pause potentiation (31.2%), was noted in the trametinib-treated slice. The increase in post-pause potentiation was less pronounced in rapamycin-treated (26%) and absent in dasatinib-treated (<1%) slices.
Conclusions
Ex vivo analysis of cultivated and electrically stimulated RV myocardial tissue slices of a patient with RAS-CM showed decreased contractility and improved sarcoplasmic reticulum function after addition of trametinib and in part after addition of rapamycin, but not after addition of dasatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Surgical Research at the Walter Brendel Centre of Experimental Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
- German Centre for Cardiovascular Research (DZHK), Partner Site Munich, Munich Heart Alliance (MHA), Munich, Germany.
- Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, Munich, Germany.
- Department of Congenital Heart Defects and Paediatric Cardiology, German Heart Centre Munich, Technical University of Munich School of Medicine and Health, Munich, Germany.
- Department of Congenital and Pediatric Heart Surgery, German Heart Centre Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany.
- Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, LMU Munich, Munich, Germany.
ORCID-Profile: Jules Hamers, Payel Sen, Andreas Dendorfer, Daphne Merkus, Cordula M Wolf
Förderung
- Deutsches Zentrum für Herz-Kreislaufforschung
- Deutsche Herzstiftung e.V.
Zitieren
APA
Hamers, J., Sen, P., Murthi, S. R., Papanakli, L., von Stumm, M., Baessato, F., Cleuziou, J., Meierhofer, C., Ewert, P., Dendorfer, A., Merkus, D., & Wolf, C. M. (2025). Trametinib Alters Contractility of Paediatric Noonan Syndrome-Associated Hypertrophic Myocardial Tissue Slices. ESC Heart Failure, 12(3), 2321-2334. https://doi.org/10.1002/ehf2.15173
Vancouver
Hamers J, Sen P, Murthi SR, Papanakli L, von Stumm M, Baessato F, et al. Trametinib Alters Contractility of Paediatric Noonan Syndrome-Associated Hypertrophic Myocardial Tissue Slices. ESC Heart Failure. 2025;12(3):2321-2334. doi:10.1002/ehf2.15173
BibTeX
@article{Hamers2025,
author = {Hamers, Jules and Sen, Payel and Murthi, Sarala Raj and Papanakli, Laura and von Stumm, Maria and Baessato, Francesca and Cleuziou, Julie and Meierhofer, Christian and Ewert, Peter and Dendorfer, Andreas and Merkus, Daphne and Wolf, Cordula M},
title = {Trametinib Alters Contractility of Paediatric Noonan Syndrome-Associated Hypertrophic Myocardial Tissue Slices},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {3},
pages = {2321--2334},
doi = {10.1002/ehf2.15173}
}
EUVIMED